16Dec 2021
Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States

Cost‐Effectiveness of Second‐Line Empagliflozin versus Liraglutide for Type 2 Diabetes in the United States

To estimate the cost‐effectiveness of sequential use of the sodium‐glucose co‐transporter 2 inhibitor empagliflozin and glucagon‐like peptide‐1 receptor agonist liraglutide after metformin in patients with type 2 diabetes (T2D) from the United States (US) payer perspective. An economic simulation model with a lifetime horizon was developed to estimate T2D‐related complications (including CV death, myocardial infarction, stroke, and renal outcomes) using EMPA‐REG OUTCOME data or United Kingdom Prospective Diabetes Study risk equations, in patients with or without a history of cardiovascular disease (CVD), respectively. Evidence synthesis methods were used to provide effectiveness inputs for empagliflozin and liraglutide. Population characteristics, adverse event rates, treatment escalation, costs ($2019) and utilities (both discounted 3%/year) were taken from US sources...

  • #endo-diabetology

Like

Save

Share